A
Andrew Loblaw
Researcher at Sunnybrook Health Sciences Centre
Publications - 237
Citations - 7626
Andrew Loblaw is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Prostate cancer & Brachytherapy. The author has an hindex of 37, co-authored 215 publications receiving 6164 citations. Previous affiliations of Andrew Loblaw include North York General Hospital & University of Toronto.
Papers
More filters
Journal ArticleDOI
Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
TL;DR: A low rate of prostate cancer mortality was observed among the patients who were reclassified as higher risk and who were treated, PSA failure was relatively common and other-cause mortality accounted for almost all of the deaths.
Journal ArticleDOI
Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Laurence Klotz,Laurence Klotz,Danny Vesprini,Danny Vesprini,Perakaa Sethukavalan,Perakaa Sethukavalan,Vibhuti Jethava,Vibhuti Jethava,Liying Zhang,Liying Zhang,Suneil Jain,Toshihiro Yamamoto,Toshihiro Yamamoto,Alexandre Mamedov,Alexandre Mamedov,Andrew Loblaw,Andrew Loblaw +16 more
TL;DR: Active surveillance for favorable-risk prostate cancer is feasible and seems safe in the 15-year time frame and the mortality rate is consistent with expected mortality in favorable- risk patients managed with initial definitive intervention.
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
Exercise for people with cancer: a clinical practice guideline
TL;DR: There is sufficient evidence to show that exercise provides benefits in quality of life and muscular and aerobic fitness for people with cancer both during and after treatment, and that it does not cause harm.
Journal ArticleDOI
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian M. Duchesne,Henry H. Woo,Julie K. Bassett,Steven J. Bowe,Catherine D'Este,Mark Frydenberg,Madeleine King,Leo Ledwich,Andrew Loblaw,Shawn Malone,Jeremy Millar,Roger L. Milne,Rosemary Smith,Nigel Spry,Martin R. Stockler,Rodney Syme,Keen Hun Tai,Sandra Turner +17 more
TL;DR: Immediate receipt of androgen-deprivation therapy significantly improved overall survival compared with delayed intervention in men with PSA-relapsed or non-curable prostate cancer.